Related Experiment Videos
Low-Dose Colchicine for Secondary Prevention in Patients With Chronic Coronary Syndrome: A Multicenter Real-World
Ecem Gürses1, Mustafa Doğduş2, Umut Uyan3
1Department of Cardiology, Bakırçay University Çiğli Training and Research Hospital, İzmir, Turkey.
Summary
Low-dose colchicine significantly improved functional capacity and reduced angina symptoms in patients with chronic coronary syndrome (CCS). This real-world study found colchicine to be a safe and effective adjunctive therapy for secondary prevention and symptom management.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Chronic coronary syndrome (CCS) patients experience persistent symptoms and reduced quality of life despite standard treatments.
- Low-dose colchicine shows promise in randomized trials, but real-world data on its impact on CCS functional capacity and angina is limited.
Purpose of the Study:
- To evaluate the real-world effectiveness of low-dose colchicine in improving functional capacity and angina-related outcomes in CCS patients.
- To assess the safety and tolerability of low-dose colchicine for secondary prevention in a large, multicenter cohort.
Main Methods:
- A multicenter, real-world observational study involving 614 CCS patients receiving low-dose colchicine for secondary prevention.
- Assessment of functional capacity and quality of life using the Seattle Angina Questionnaire (SAQ) pre- and post-treatment.
- Evaluation of changes in physical activity, angina frequency, nitroglycerin use, treatment satisfaction, CCS angina class, clinical outcomes, and adverse events.
Main Results:
- Colchicine therapy led to significant improvements in functional capacity (walking, household activities, heavy object carrying) and reduced angina frequency and nitroglycerin use (all p < 0.001).
- Patient-reported outcomes showed increased treatment satisfaction and decreased life enjoyment limitations (p < 0.001), with a decrease in CCS angina class.
- A clinically meaningful improvement in SAQ score was achieved by 78.7% of patients; hospitalization (9.0%), revascularization (4.4%), and GI adverse effects (9.4%) were reported.
Conclusions:
- Low-dose colchicine therapy in a real-world CCS cohort demonstrated significant improvements in functional capacity, angina severity, and quality of life.
- The therapy exhibited an acceptable safety profile, with a high rate of clinically meaningful patient-reported improvements.
- Colchicine is supported as an effective adjunctive therapy for secondary prevention and symptom control in routine clinical practice for CCS.
Related Concept Videos
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...